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ABSTRACT
To determine the long-term outcome of patients undergoing unrelated donor transplantation (URD) after a
reduced intensity conditioning (RIC) regimen, we performed a retrospective analysis of the transplant out-
comes of the first 5 years of RIC experience as reported to the National Marrow Donor Program (NMDP).
Patients were included if they were older than 18 years and had undergone a URD transplant procured through
the NMDP from January 1, 1996 until May 31, 2001, with an RIC regimen for a hematologic malignancy. The
number of URDs performed using an RIC increased from 59 during 1996 to 1999, to 149 in the year 2000. RIC
recipients were older (53 vs. 33 years) and had a higher likelihood of having advanced disease (81% vs. 51%)
when compared to patients undergoing a myeloablative conditioning regimen during the same time period.
The 5-year survival rate is 23% (95% confidence interval [CI]; 18, 28), whereas the 5 year incidence of
progression/relapse is 43.4% (95% CI; 37,49). Prognostic factors for better overall survival on multivariate
analysis were earlier disease stage, longer time to transplant from diagnosis, better HLA match, >90%
performance score, and use of peripheral blood stem cells. This analysis demonstrates that long-term survival
and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning.
However, only prospective trials will define the optimal role of this therapy in patients with hematologic malig-
nancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials.
© 2007 American Society for Blood and Marrow Transplantation
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Unrelated donor (URD) cells represent the most
ommon alternative source of hematopoietic stem
ells for patients with hematologic malignancies who
o not have an HLA compatible donor within the
amily [1]. High-dose chemoradiotherapy followed by
nfusion of URD stem cells can provide long-term
isease control for a signiﬁcant fraction of patients
ith a variety of malignant and nonmalignant disor- [
44ers. However, this procedure is also associated with a
igniﬁcant risk of morbidity and mortality primarily
ecause of graft-versus-host disease (GVHD) and in-
ectious complications [1,2].
The most important risk factors for transplant-
elated morbidity and mortality after conventional
RD transplantation are degree of HLA matching,
isease status at the time of transplant, patient and
onor age, as well as pre transplant performance status
1-4]. Non-relapse mortality (NRM) rates of over
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Reduced-Intensity Conditioning for UD Progenitor Cell Transplantation 8450% are commonly reported in patients over the age
f 40; thus, many centers are restricting the use
f unrelated hematopoietic cell transplantation to
ounger patients with good performance status and
inimal comorbidities. However, older and debili-
ated patients represent a large fraction of the patients
ith hematologic malignancies who could potentially
eneﬁt from an allograft through a graft-versus-
alignancy effect or the recovery of a functioning
one marrow.
In an effort to reduce NRM in older and medically
ebilitated patients many investigators have explored
he concept of reduced-intensity conditioning (RIC)
egimens [5-9]. The rationale for this approach lies in
he hypothesis that less intense preparative regimens
ill result in less recipient tissue damage and less
elease of inﬂammatory cytokines resulting in fewer
oxicities and a lower incidence of GVHD [10,11].
The feasibility and efﬁcacy of RIC regimens has
een documented in multiple studies, mostly using
atched sibling donors [5-9,12]. Recently, single and
ulti-institution reports demonstrating the feasibility
f RIC regimens using unrelated and mismatched
onors have also been reported [6,12-14]. We per-
ormed a retrospective analysis of transplant outcomes
n patients receiving an RIC regimen as reported to
he National Marrow Donor Program (NMDP) to
escribe the long-term outcomes of patients treated
ith an RIC regimen followed by URD progenitor
ell transplantation, and to deﬁne potential prognostic
actors for outcome.
ATIENTS AND METHODS
he National Marrow Donor Program
The NMDP was established in 1986 by an act of
nited States Congress, and is currently under con-
ract with the Health Resources and Services Admin-
stration. The policies and procedures of the NMDP
ave been previously described [15]. The NMDP not
nly facilitates the search and procurement of unre-
ated donor progenitor cells and cord blood units, but
lso maintains a prospective database of transplanted
atients that includes pretransplant demographics,
isease speciﬁc variables, as well as posttransplant out-
omes. In July 2004, the NMDP partnered with the
edical College of Wisconsin’s International Bone
arrow Transplant Registry and Autologous Blood
nd Marrow Transplant Registry to form the Center
or International Blood and Marrow Transplant Re-
earch (CIBMTR). The NMDP conducts its research
rogram through the CIBMTR.
atient Eligibility
To qualify for the analysis patients had to meet the
ollowing criteria: (1) undergone URD transplant wrom 1/96 to 05/01; (2) had a malignant disorder as
eﬁned by the NMDP recipient baseline and trans-
lant data form; (3) 18 years or older at the time of the
ransplant; (4) received a conditioning regimen fulﬁll-
ng 1 of the following criteria: (a) 500 cGy or less of
otal body irradiation (TBI); (b) 9 mg/kg or less of
otal busulfan dose; (c) 140 mg/m2 or less total mel-
halan dose; (d) regimen included a purine analog
ither ﬂudarabine, cladribine, or pentostatin.
These regimens all fulﬁlled the criteria used to
eﬁne an RIC regimen as suggested by Champlin
t al. [16-19], which include reversible myelosuppres-
ion within 28 days if given without stem cell support,
ixed chimerism in a signiﬁcant proportion of pa-
ients after allogeneic transplantation and limited ex-
ramedullary toxicity. Using these criteria, a total of
85 patients were available for analysis. Univariate and
ultivariate analyses of pre- and peritransplant vari-
bles was performed for the following transplant out-
omes: acute and chronic GVHD (aGVHD and
GVHD), NRM, and overall survival.
ata Collection Methods
Data from each transplant center were collected
rospectively on standardized forms. The NMDP val-
dated the data for consistency and accuracy. All pa-
ients and donors were treated under local institu-
ional review board (IRB) guidelines and provided
ritten informed consent for treatment. Procedures
or donor and recipient data submission to the NMDP
ere reviewed and approved by the NMDP IRB. All
urviving recipients included in this analysis were ret-
ospectively contacted and provided informed consent
or participation in the NMDP research program.
nformed consent was waived by the NMDP IRB for
ll deceased recipients. To address bias introduced by
nclusion of only a proportion of surviving patients
those who consented) but all deceased recipients, a
ample of deceased patients was selected using a
eighted randomized scheme that adjusts for overrepre-
entation of deceased patients in the consented cohort.
Transplantation was done by the centers using
heir local protocols for conditioning regimen and
VHD prophylaxis. HLA matching for hematopoi-
tic stem cell transplantation was based on antigen or
llele identity between donor and recipient. Strategies
or selecting a partially HLA-mismatched donor var-
ed when a fully matched donor could not be identiﬁed.
election of the RIC regimen for transplantation was at
he discretion of the transplant center, and the rationale
or this selection was not collected by the NMDP.
nivariate Analysis and Multivariate Analysis
Nonrelapse mortality was deﬁned as death from
ny cause other than relapse. aGVHD and cGVHD
ere scored according to standard published criteria
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S. Giralt et al.84620,21]. Overall survival (OS) rates were calculated by
he methods of Kaplan and Meier, and comparisons
etween groups were made using the log-rank statis-
ics [22,23]. Probabilities of aGVHD and cGVHD,
RM, and relapse were calculated using cumulative in-
idence estimates to accommodate competing risks [24].
Cox proportional hazards regression was used to
t a multivariate model for OS. Factors considered for
model were HLA match, year of transplant, source
f stem cells, diagnosis, donor/recipient CMV status,
isease status prior to transplant, recipient age, use of
ntithymocyte globulin (ATG/ALG), Karnofsky per-
ormance score prior to transplant, ABO compatibil-
ty, prior transplant, and donor/recipient sex match.
isk factors were included in the ﬁnal model only if
he Wald chi-square statistic yielded a P-value  .05
25]. The assumption of proportional hazards for each
ovariate was tested using time-dependent covariates.
ossible interactions between factors were investi-
ated, but none were signiﬁcant at a P-value .01.
himerism
A variety of methods were used to determine chi-
erism as reported by the transplant centers to the
MDP including conventional cytogenetics, restric-
ion fragment length polymorphisms, and polymerase
hain reaction [26]. The results of the ﬁrst chimerism
nalysis (usually performed between 1 and 3 months
osttransplant) are reported.
ESULTS
atient and Treatment Characteristics
Patient and treatment characteristics are summa-
ized in Table 1. In brief, median age was 53 years
range: 18-79). Sixty-four percent of the recipients
ere male. Non-Hodgkin’s lymphoma was the most
ommon indication for URD transplantation with
IC followed by acute myelogenous leukemia (AML)
nd chronic myelogenous leukemia (CML). The me-
ian time from diagnosis to transplant was 23 months
range: 0.7-308). The conditioning regimen most
ommonly included ﬂudarabine in combination with
BI (30%), busulfan (23%), melphalan (20%), or
yclophosphamide (16%). GVHD prophylaxis con-
isted of either cyclosporine or tacrolimus in combi-
ation with other agents. ATG or ALG was adminis-
ered to 31% of the recipients. The regimens and
VHD prophylaxis used stratiﬁed by diagnosis are
ummarized in Table 2.
haracteristics of Reduced Intensity Conditioning
ecipients Compared to Conventional Allografts
When compared to patients undergoing an URD
ransplant using a conventional myeloablative condi- Rioning regimen during the same time period, recipi-
nts of RIC were older (median age: 53 vs. 33) and had
higher likelihood of having Hodgkin’s Disease, non-
odgkin lymphoma, or a Plasma Cell disorder (39%
s. 8%). These patients also had a higher likelihood of
aving advanced disease (81% vs. 51%) and receive
eripheral blood stem cells (PBSC) rather than bone
arrow (46% vs. 5%). Table 3 summarizes the dif-
erences between recipients of RIC and the patients
ho underwent an ablative URD transplant during
he same years.
utcomes
Chimerism data between 1 and 3 months post-
ransplant were available for 234 patients. The median
ercentage of donor cells was 84% (range: 0-100). A
otal of 21 (11%) patients never had any evidence of
onor cell engraftment (i.e., primary graft failure).
The cumulative incidence of grade II-IV aGVHD
or the whole group was 39% (95% conﬁdence inter-
al [CI]; 33;45), the cumulative incidence of grade
II-IV aGVHD was 22% (95%CI 17;27). The cumu-
ative incidence of cGVHD at 2 years was 41% (95%
I; 35;46). The NRM rate at 3 months was 19% (95%
I: 15;24). Currently 66 patients are alive at a median
f 61 months (range: 13-87 months). The 5 year OS
ate is 23% (95% CI: 18,28). A total of 125 patients
ave relapsed or progressed, the relapse rate at 5 years
or the whole group was 43% (95% CI: 37,49).
Because of the high degree of the patients, disease,
isease state, and treatment heterogeneity, multivari-
te analysis was performed only for OS. Multiple
ariables were considered for the multivariate analysis,
mong them recipient age, disease stage, performance
tatus, year of transplant, time from diagnosis to trans-
lant, HLA matching, donor-recipient cytomegalovi-
us (CMV) status, donor-recipient sex match, stem
ell source, and whether the URD transplant was a
rst or second transplant. Conditioning regimens,
VHD prophylaxis, and the source of stem cells are
enerally considered together as a “package” for he-
atopoietic transplantation at most centers. As such,
heir effects on transplant outcome cannot be consid-
red independently. Table 4 summarizes transplant
utcome. Table 5 summarizes those factors signiﬁ-
antly associated with increased risk of death include
se of bone marrow as the source of stem cells, inter-
ediate or advanced disease at transplant, Karnofsky
erformance score 90, HLA mismatch between do-
or and recipient, and time from diagnosis to trans-
lant shorter than 12 months.
ISCUSSION
It has now been 10 years since the ﬁrst trials of
IC regimens for allogeneic transplantation in pa-
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Reduced-Intensity Conditioning for UD Progenitor Cell Transplantation 847ients with hematologic malignancies were described.
IC regimens can exploit a graft versus tumor effect
n conjunction with limited peritransplant morbidity
6-9,11-14]. Data from the IBMTR and the EBMT
ave shown a dramatic increase in the number of
llografts that are being performed using RIC regi-
ens [27,28]. Although the deﬁnition of an RIC reg-
men is imprecise, these regimens typically involve
gents that are used in the setting of standard myeloa-
lative regimens at lower doses, and at least for cyclo-
hosphamide, melphalan, and TBI have been shown
o be associated with reversible myelosuppression
16-19]. The deﬁnition of RIC used in this analysis has
een broadly used by the CIBMTR and the NMDP in
erforming other retrospective analyses.
In this analysis we describe the long-term out-
omes of patients who underwent a URD transplant
fter an RIC regimen during the ﬁrst 5 years of use of
his treatment modality. Our main objective was to
etermine whether long-term survival and disease
ontrol was feasible, and because of the cohort heter-
geneity we did not attempt to analyze the efﬁcacy of
able 1. (Continued)
Variable N Eval. N %
Fludarabine  cyclophosphamide 
other 46 (16)
Fludarabine  melphalan < 140 mg/
m2  other 57 (20)
Fludarabine  busulfan < 9 mg/kg 
other 66 (23)
Fludarabine  cytarabine  other 20 (7)
Other 10 (4)
ource of stem cells 285
PBSC 131 (46)
Bone marrow 154 (54)
VHD prophylaxis 285
Cyclosporine based 151 (54)
Cyclosporine  mycophenolate
mofetil  other 107 (38)
Cyclosporine  methotrexate 
other 7 (2)
Cyclosporine  other 37 (13)
Tacrolimus based 130 (45)
Tacrolimus  mycophenolate
mofetil  other 12 (4)
Tacrolimus  methotrexate  other 100 (35)
Tacrolimus  other 18 (6)
Other 4 (1)
TG/ALG prior to transplant 285
Yes 88 (31)
No 197 (69)
irst transplant 285
Yes 186 (63)
No 99 (37)
LA indicates human leukocyte antigen; CMV, cytomegalovirus;
TBI, total body irradiation; PBSC, peripheral blood stem cells;
GVHD, graft-versus-host disease; ATG, antithymocyte globu-
lin; ALG, antilymphocyte globulin.able 1. Characteristics of Patients Receiving URD Cell Transplants
sing Reduced Intensity Conditioning Regimens
Variable N Eval. N %
ecipient sex 285
Female 102 (36)
Male 183 (64)
ecipient age in years 285
ecipient age median (range) 53 (18-79)
<40 54 (19)
40 to 50 61 (21)
>50 170 (59)
iagnosis and diseases stage 285
Acute lymphocytic leukemia 9 (4)
CR1/CR2 2/2 (2)
>CR2 3 (1)
Not in remission 2 (1)
Acute myelogenous leukemia 60 (21)
CR1/CR2 22/14 (12)
>CR2 3 (1)
Not in remission 21 (8)
Chronic myelogenous leukemia 43 (15)
First chronic phase 12 (4)
Advanced CML/myeloproliferative
disease (MPD) 31 (11)
Chronic lymphocytic leukemia 30 (10)
Hodgkin’s lymphoma 16 (6)
Non-Hodgkin’s lymphoma 65 (22)
Myelodysplastic syndromes 28 (10)
Plasma cell disorders 34 (11)
erformance status prior to transplant
(Karnofsky) 285
90-100 167 (59)
<90 99 (35)
Missing 19 (7)
ime from diagnosis to transplant in
months 285
Median (range) 23 (0.7-308)
0-12 62 (22)
12-36 117 (41)
>36 101 (35)
Missing 5 (2)
onor age in years 285
Median (range) 37 (19-59)
onor/recipient sex match 285
Female donor-female recipient 55 (19)
Female donor-male recipient 43 (15)
Male donor-female recipient 47 (16)
Male donor-male recipient 140 (49)
LA match (intermediate resolution
for -A, -B, and high resolution for
-DRB1) 285
Match 248 (87)
Mismatch 37 (13)
onor/recipient CMV status 285
Donor negative/recipient negative 70 (24)
Donor negative/recipient positive 98 (34)
Donor positive/recipient negative 39 (14)
Donor positive/recipient positive 62 (22)
Unknown 16 (6)
onor/recipient blood group match 285
Match 116 (41)
Mismatch 167 (58)
Missing 2 (1)
onditioning regimen 285
Fludarabine  <500 cGy TBI IC for any speciﬁc indication.
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S. Giralt et al.848The observation that at 5 years posttransplant
3% of patients are alive and 18% are alive and free of
rogression or relapse demonstrates that long-term
urvival and disease control is feasible with this treat-
able 2. Distribution of Diagnosis and GVHD Prophylaxis by Conditio
Total Flu/AraC Flu
iagnosis
LL, AML, MDS 97 1 2
ML and MPD 43 1 1
LL, lymphoma 111 18 1
CD 34 0
otal 285 20 6
VHD Prophylaxis
SA based 151
SA-MMF 107 0
SA-MTX 7 1
SA-other 37 1 1
acro based 134
acro-MMF 12 0
acro-MTX 100 16 2
acro-other 18 2 1
ther 4 0
otal 285 20 6
LL indicates acute lymphocytic leukemia; AML, acute myelogeno
nous leukemia; MPD, myeloproliferative disorder; CLL, chronic
host disease; CSA, cyclosporine; MMF, mycophenolate mofetil
able 3. Characteristics Of RIC Patients Compared To Conventional M
Variable
RI
N Eval.
ecipient sex 285
Female
Male
ecipient age in years 285
ecipient age median (range) 5
<40
40-50
>50
iagnosis 285
ALL
AML
CML
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Myelodysplastic disorders
Plasma cell disorders
Other leukemia
isease stage prior to transplant 285
CR1/CR2/CP1
Other
erformance status prior to transplant 285
90 or higher
<90
Missing
TG/ALG prior to transplant 285
Yes
No
ource of stem cell 285
PBSC
Marrow 154ent strategy, despite the older age and that only 19%
f patients underwent this treatment early in the
ourse of their disease. This analysis was not intended
o deﬁne the relative beneﬁt of URD transplantation
egimen
Flu/Cyc Flu/Mel Flu/TBI Others
9 22 34 4
6 7 18 0
29 16 23 6
2 12 11 0
46 57 86 10
15 5 71 8
1 2 0 0
12 8 4 0
3 4 1 0
15 37 3 1
0 0 6 0
0 1 1 1
46 57 86 10
emia; MDS, myelodysplastic syndromes; CML, chronic myeloge-
ocytic leukemia; PCD, plasma cell disorders; GVHD, graft-versus-
, methotrexate; Tacro, tacrolimus.
ative URD Allografts Over The Same Time Period
ent Myeloablative
% N Eval. N %
5653
(36) 2376 (42)
(64) 3277 (58)
5653
9) 33 (0.2-67)
(19) 3719 (66)
(21) 1301 (23)
(60) 633 (11)
5653
(4) 1206 (21)
(21) 1486 (26)
(15) 1778 (31)
(6) 42 (1)
(22) 330 (6)
(10) 570 (10)
(11) 76 (1)
(10) 165 (3)
5653
(19) 2758 (49)
(81) 2895 (51)
5653
(58) 3930 (70)
(35) 1618 (29)
(7) 105 (2)
5653
(31) 1193 (21)
(69) 4460 (79)
5653
(46) 284 (5)ning R
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Reduced-Intensity Conditioning for UD Progenitor Cell Transplantation 849ith an RIC regimen over other conventional trans-
lant and nontransplant approaches, but it should pro-
ide the basis for the design and implementation of
ontrolled clinical trials aimed at deﬁning the role of
IC in speciﬁc disease entities and stages [29-32].
Disease stage, performance status, stem cell
ource, HLA matching, and timing of transplant
merged as the most important prognostic factors for
urvival after RIC URD transplant, and should be
onsidered when planning and designing future trials
ith this treatment modality. Patients with more ad-
anced disease had a 77% increase risk of death when
ompared to patients transplanted early in the course
f their disease. This increase in deaths was related
able 4. Transplant Outcomes after RIC Conditioning
Outcome Estimate (95% CI)
urvival
at 1 year 44.2% (38.8%-50.4%)
at 3 years 28.3% (23.5%-34.1%)
at 5 years 23.0% (18.5%-28.5%)
FS
at 1 year 30.9% (25.9%-36.7%)
at 3 years 22.2% (17.9%-27.7%)
at 5 years 18.0% (14.0%-23.2%)
RM
at 100 days 18.8% (14.5%-23.6%)
at 1 year 30.1% (24.9%-35.6%)
at 3 years 35.9% (30.3%-41.5%)
at 5 years 38.6% (32.9%-44.3%)
elapse/progression
at 1 year 39.0% (33.3%-44.7%)
at 3 years 41.9% (36.1%-47.6%)
at 5 years 43.4% (37.5%-49.1%)
hronic GVHD
at 1 year 38.6% (32.9%-44.3%)
at 3 years 40.8% (35.0%-46.5%)
at 5 years 40.8% (35.0%-46.5%)
FS indicates progression free survival; NRM, Nonrelapse mortal-
ity; GVHD, graft-versus-host disease; CI, conﬁdence interval.
able 5. Factors Related to Risk of Death as Identiﬁed by Multivariate
Variable Level
tem cell source BM
PB
isease stage CR1/CP1/RA/RAR
Intermediate/Adv
LA matching Matched
Mismatched
arnofsky Score >90
<90
Missing
ime from diagnosis to transplant
<12 months
12 to 36 months
>36 months
R indicates relative risk; CI, conﬁdence interval; RA, refractory
complete remission; CP1, ﬁrst chronic phase.Two degrees of freedom test.rimarily to increases in relapse risk but also in NRM
ates. These data support continued exploration of
his treatment modality in patients with hematologic
alignancies early in the course of the disease, partic-
larly in the absence of other effective therapies (i.e.,
DS and acute leukemia). In other hematologic ma-
ignancies this treatment option needs to be explored
n the context of new emerging nontransplant thera-
ies.
We observed a potential advantage of PBSC over
one marrow that requires further study. Previously,
n advantage for PBSC compared to bone marrow has
nly been demonstrated using low-dose TBI condi-
ioning, where a higher risk of graft failure was ob-
erved using marrow grafts [32]. In this larger analysis,
he use of PBSC was associated with superior OS
ndependent of conditioning regimen. This observa-
ion parallels the observations after sibling and unre-
ated donor transplantation in adults [33-38]. How-
ver, conﬁrmatory data from prospective, randomized
omparisons of peripheral blood versus bone marrow
nrelated grafts are still lacking. An ongoing Blood
nd Marrow Transplant Clinical Trials Network
tudy (BMT CTN 0201) may answer this important
uestion.
Dose intensity has been the mainstay of conven-
ional allografting, and single institutional studies
ave shown that myelogenous leukemia patients re-
ults fare better using more intense regimens, often
ncluding either melphalan or busulfan [39]. Variabil-
ty in RIC regimens may yield different outcomes in
peciﬁc diseases and disease stages. This retrospective
nalysis did not identify any disease or disease state in
hich 1 regimen was associated with superior out-
omes. Therefore, carefully designed prospective tri-
ls in individual diseases are essential to determine the
ontribution of the speciﬁc conditioning regimen to
ffective disease control.
is
N RR (95%CI) P-Value
149 1.00
124 0.65 (0.48-0.86) .003
36 1.00
237 1.77 (1.09-2.86) .020
239 1.00
34 1.51 (1.01-2.26) .043
159 1.00 .031a
98 1.49 (1.10-2.01) .009
16 1.08 (0.58-2.01) .804
<.001a
62 1.00
117 0.60 (0.41-0.88) .009
94 0.44 (0.29-0.67) <.001
ia; RARS, refractory anemia with ringed sideroblasts; CR1, ﬁrstAnalys
S
anced
anem
c
a
d
t
w
[
s
d
i
d
t
r
i
c
r
o
O
c
r
s
a
R
c
m
t
e
t
i
R
s
n
A
i
m
i
A
v
I
t
B
v
f
t
A
c
B
B
C
S
C
C
I
I
P
C
M
g
K
M
c
U
t
G
p
p
S
C
m
U
I
T
d
N
N
a
g
R
F
s
S. Giralt et al.850As with conventional ablative transplantation the
auses of treatment failure remain GVHD, infections,
nd disease recurrence. These, however, may be more
ifﬁcult to control or have a more serious impact on
he older and debilitated patients with comorbidities
ho are currently being treated with RIC transplants
40-42]. The data from these ﬁrst 285 patients under-
core the need for careful selection of patients and
onors. Other large retrospective single and multi-
nstitutional analysis has reported long-term outcome
ata of patients undergoing RIC unrelated donor
ransplantation. Among these, the Seattle Consortium
ecently reported the results of 122 patients undergo-
ng allogeneic transplantation using ﬂudarabine in
ombination with 200 cGy of TBI, OS at 2 years was
eported as 48%; interestingly, in this study recipients
f URD stem cells actually had a trend toward a better
S at 2 years (63% vs. 44%) than patients receiving
ells from a matched related donor, because of a lower
isk of relapse (16% vs. 50%) (45). Longer follow-up
tudies will be important to assess the durability of this
pparent beneﬁt.
In conclusion, URD transplantation after an
IC can result in long-term survival and disease
ontrol for a fraction of patients with hematologic
alignancies. Patients with advanced disease at the
ime of transplant do poorly, and should be consid-
red for RIC therapy only in the context of a clinical
rial incorporating new agents or strategies aimed at
mproving long-term disease control. The role of
IC in individual diseases particularly in early
tages requires well-controlled trials against alter-
ative transplant as well as nontransplant strategies.
ccording to our analysis, these studies should take
nto account the impact of disease stage, HLA
atching, and stem cell source when designed and
igure 1. Overall survival by disease category after nonablative
tem cell transplant.mplemented (Table 5, Figure 1).CKNOWLEDGMENTS
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